Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
100 results about "Peripheral Artery Diseases" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Occlusion-crossing devices, imaging, and atherectomy devices
ActiveUS20120253186A1Avoid damageIncrease relative motionUltrasonic/sonic/infrasonic diagnosticsDiagnostic markersCatheter devicePeripheral Artery Diseases
The present invention relates to: (1) guidewire support / placement catheters; (2) support / placement catheters with imaging; (3) atherectomy catheters, (4) atherectomy catheters with imaging, (5) occlusion crossing catheters, and (6) occlusion crossing catheters with imaging as well as methods for using them to treat disorders (and particularly peripheral artery disease) and systems including them.
Owner:AVINGER
Synthetic apelin mimetics for the treatment of heart failure
ActiveUS8673848B2Extended half-lifeIncrease constraintsNervous disorderSkeletal disorderCardiac fibrosisVentricular tachycardia
The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Owner:NOVARTIS AG
Apparatus and method for an ultrasonic medical device to treat peripheral artery disease
InactiveUS20050043753A1Effective timeSimple, user-friendlyUltrasound therapyCannulasCavitationTransverse plane
An apparatus and method for an ultrasonic medical device to treat peripheral artery disease. The ultrasonic medical device comprises an ultrasonic probe having a proximal end, a distal end and a longitudinal axis therebetween. The ultrasonic probe is inserted into an insertion point in a leg opposite the leg having an occlusional deposit and is moved adjacent to the occlusional deposit. An ultrasonic energy source is activated to generate a transverse ultrasonic vibration along at least a portion of the longitudinal axis of the ultrasonic probe. The transverse ultrasonic vibration creates a plurality of transverse nodes and a plurality of transverse anti-nodes along the longitudinal axis of the ultrasonic probe, generating cavitation in a medium surrounding the ultrasonic probe to ablate the occlusional deposit causing peripheral artery disease.
Owner:CYBERSONICS
Occlusion-crossing devices, imaging, and atherectomy devices
ActiveUS8644913B2Avoid damageIncrease relative motionUltrasonic/sonic/infrasonic diagnosticsCannulasCatheterArtery
The present invention relates to: (1) guidewire support / placement catheters; (2) support / placement catheters with imaging; (3) atherectomy catheters, (4) atherectomy catheters with imaging, (5) occlusion crossing catheters, and (6) occlusion crossing catheters with imaging as well as methods for using them to treat disorders (and particularly peripheral artery disease) and systems including them.
Owner:AVINGER
Synthetic apelin mimetics for the treatment of heart failure
ActiveUS20130196899A1Extended half-lifeIncrease constraintsNervous disorderSkeletal disorderCardiac fibrosisVentricular tachycardia
The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Owner:NOVARTIS AG
Beta2-microglobulin and c reactive protein (CRP) as biomarkers for peripheral artery disease
InactiveUS20090042214A1Peptide/protein ingredientsMicrobiological testing/measurementArtery of PercheronAtheroma
The present invention relates to use of β-2-microglobulin (B2M or β2M) and C-reactive protein (CRP) levels as biomarkers of peripheral artery disease and / or atherosclerosis.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Treatment of peripheral vascular disease by baroreflex activation
InactiveUS20080167690A1Relieve symptomsImprove local vasodilationElectrotherapyDiseaseVascular disease
Peripheral vascular diseases, such as peripheral artery disease, are treated by activating a baroreflex response of a patient suffering from or at risk of these conditions. In the exemplary embodiments, the baroreflex response is activated using an implantable system comprising a controller and a device which activates the baroreceptor or baroreceptor nerve in order to initiate the baroreflex response.
Owner:CVRX
Biomarkers for peripheral artery disease
This invention provides biomarkers whose concentrations in blood plasma are associated with the presence or absence of PAD in the patient from whom the plasma sample is taken. The invention also provides biomarkers for distinguishing between PAD patients who are long claudicators and PAD patients who are not. In addition, the invention provides methods for identifying additional biomarkers, methods for detecting the biomarkers in patients, and methods for identifying agents, including pharmaceutical agents, which interact with the biomarkers and are useful for preventing or treating PAD in patients.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1
Synthetic linear apelin mimetics for the treatment of heart failure
InactiveUS20140155315A1Extended half-lifeIncrease constraintsNervous disorderPeptide/protein ingredientsCardiac fibrosisVentricular tachycardia
The invention provides a synthetic polypeptide of Formula I′ (SEQ ID NO: 1):X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13 Ior an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Owner:NOVARTIS AG
Bioresorbable Polymer Scaffold Treatment of Coronary and Peripheral Artery Disease in Diabetic Patients
Methods of treating coronary and peripheral artery disease in diabetic patients with bioresorbable polymer stents are described. The stents may include everolimus.
Owner:ABBOTT CARDIOVASCULAR
Circulation Monitoring System
Owner:SEMLER SCI
Novel fatty acids and their use in conjugation to biomolecules
The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease / steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Owner:NOVARTIS AG
Dynamic optical tomographic imaging devices, methods and systems
The disclosed subject matter includes optical tomographic systems for acquiring and displaying dynamic data representing changes in a target tissue sample to external provocation. For example, the disclosed devices, methods and systems may be used for quantifying dynamic vascular changes caused by imposed blood pressure changes for diagnosing peripheral artery disease.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Portable Therapeutic Device Using Rotating Static Magnetic Fields
The present invention provides a portable therapeutic device for treatment of dyslipidemia, hyperviscosaemia, diabetic neuropathy, and peripheral artery disease, using rotating Static Magnetic Fields (rSMF). The device comprises a two part plastic housing with a handle and a designated treatment area, a DC motor with microcontroller and a cylindrically shaped magnet roller, which comprises magnets tightly fitted into a stainless steel sleeve capped with two bearing shafts protruded on each end. The magnet roller assembly rotates freely inside the housing with little clearance at assigned low frequency in line with the DC motor axis driven by magnetic torque from magnetic couplings, which include equally sized quad-pole magnet plates on each coupling base. The rSMF-based device produces an inhomogeneous surface intensity of 4000-7000 Gauss from its dual-pole or quad-pole parallel circuitry for an effective treatment regimen of the indicated disorders.
Owner:DEVICE THERAPEUTICS
Cell suspension for use in the treatment of lower extremity peripheral artery disease
ActiveUS20180055884A1Mammal material medical ingredientsBlood/immune system cellsDiseaseWhite blood cell
The present invention refers to a cell suspension of autologous or allogeneic, preferably autologous, adult bone marrow-derived white blood cells, preferably derived from the crest of the ilium (or iliac crest), enriched for mononuclear cells, meaning more than 25% of the white blood cells (WBCs) present in the cell suspension are mononuclear cells, and comprising:A. Mononuclear cells (MNC) selected from the list comprising or consisting of:i. A population of Lymphocytes;ii. A population of Monocytes; andiii. A population of Hematopoietic stem cells expressing CD34;and wherein the cell suspension further comprises:B. Granulocytes;for use in the treatment or amelioration of lower extremity peripheral artery disease.
Owner:REXGENERO BIOSCI SL +2
Plasma H2S levels as biomarkers for vascular disease
ActiveUS9599602B2Minimal risk of harmSensitive and accurateBiocideDisease diagnosisBlood plasmaBiomarker (petroleum)
Owner:BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV & AGRI & MECHANICAL COLLEGE
Pharmaceutical formulations of nitrite and uses thereof
The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2−). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia, in particular peripheral artery disease (PAD).
Owner:THERAVASC
Monitoring Treatment of Peripheral Artery Disease (PAD) Using Diffuse Optical Imaging
A plurality of modules are simultaneously positioned at locations that correspond to different angiosomes. Each of these modules has a front surface shaped and dimensioned for contacting a person's skin, a plurality of different-wavelength light sources aimed in a forward direction, and a plurality of light detectors aimed to detect light arriving from in front of the front surface. Each module is supported by a support structure (e.g., a strap or a clip) that is shaped and dimensioned to hold the front surface adjacent to the person's skin at a respective position. Perfusion in each of the angiosomes is monitored using these modules, and the surgeon can rely on this information to guide his or her intervention.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Thioxanthine Derivatives and Their Use as Inhibitors of MPO
InactiveUS20090149475A1Prevent and slow progressionReduce riskBiocideNervous disorderMedicineDepressant
There are disclosed novel compounds of Formula (I) wherein L, R1, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardio- and cerebrovascular atherosclerotic disorders and peripheral artery disease and respiratory disorders.
Owner:ASTRAZENECA AB
Devices, methods, and systems for the treatment and/or monitoring of damaged tissue
Disclosed are methods, devices, and systems for treatment of an abnormal wound healing response. The methods, devices, and systems can be used to treat solid ulcerated tissue, such as diabetic foot ulcers (DFUs), arthritic tissue, muscle soreness, joint pain, varicose veins, obesity, and peripheral artery disease. Additionally, the methods, devices, and systems can promote the healing of xenograft, allograft, autograft, or engineered tissue following reconstruction surgery. The methods, devices, and systems include the ability to determine an optimal set of pulse parameters that are specific to wound healing. In embodiments, the methods, devices, and systems include components for guiding the user on electrode placement based on anatomical or electrical measurements, delivering a custom series of electric pulses, applying heat, and using feedback from physiologic measurements to control the device.
Owner:ADLORE INC
Synthetic linear apelin mimetics for the treatment of heart failure
InactiveUS8921307B2Extended half-lifeIncrease constraintsPeptide/protein ingredientsMetabolism disorderCardiac fibrosisVentricular tachycardia
Owner:NOVARTIS AG
Mobile plethysmographic device
ActiveUS9649039B1Improve trustThe process is simple and convenientCatheterSensorsBoth lower extremitiesPlasma viscosity
A mobile plethysmographic device for detecting a Peripheral Artery Disease (“PAD”) event or other arrhythmia event is disclosed herein. The mobile plethysmographic device generates a pleth waveform, which is automatically screened by algorithms that measure the waveform to correlate, detect and store aberrations related to heart anomalies. A peripheral artery disease event for a patient is determined based on a quantative measure of blood flow in the extremities based on the differential in amplitude in the pleth signal between the arm and the two lower extremities. The changes in amplitude from the arm and one or both lower extremities can indicate PAD.
Owner:YUKKA MAGIC LLC
Peripheral arterial disease diagnosis method based on deep learning
The invention discloses a peripheral arterial disease diagnosis method based on deep learning. According to the method, tissue blood flow change data of peripheral arterial disease patients and healthy volunteers can be acquired by utilizing the diffusion related spectrum technology against the defects of a traditional method for diagnosing peripheral arterial diseases based on ABI; the tissue blood flow data is trained based on the proposed deep learning network, key features containing peripheral arterial disease information are extracted and are trained to obtain a deep learning network model for diagnosing peripheral arterial diseases, and test set data is input into a peripheral arterial disease diagnosis model for diagnosing, so that peripheral artery diseases are diagnosed. The method overcomes the defects of existing ABI diagnosed peripheral arterial diseases, verifies the feasibility of tissue blood flow measurement for peripheral arterial disease diagnosis, and provides a newtechnology and new method for peripheral arterial disease diagnosis.
Owner:BEIJING UNIV OF TECH
Pharmaceutical formulations of nitrite and uses thereof
The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2−). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia, in particular peripheral artery disease (PAD).
Owner:THERAVASC
Beta-2 microglobulin as a biomarker for peripheral artery disease
ActiveUS7867719B2Peptide/protein ingredientsAnalysis by subjecting material to chemical reactionBiomarker (petroleum)Beta-2 microglobulin
The present invention provides β2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.
Owner:ASPIRA WOMENS HEALTH INC +2
Drug delivery device for peripheral artery disease
A medical device implantable within a peripheral vessel of the body composed of a bioresorbable polymer is disclosed. The device has a high resistance to fracture, is very flexible, and has a high crush recovery when subjected to crushing, axial, or torsional forces.
Owner:ABBOTT CARDIOVASCULAR
Method and system for assessing severity and stage of peripheral arterial disease and lower extremity wounds using angiosome mapping
The present invention provides a system for assessing the severity and stage of PAD including at least one sensor that measures skin perfusion pressure; a knowledge base that provides data on lower extremity angiosomes; and a processing device in operable communication with the sensor and the knowledge base, the processing device that outputs a visual representation of at least one of the lower extremity angiosomes that guides the sensor in the mapping of a testing site relative to a target vessel where the skin perfusion pressure measurement will be taken.
Owner:OPTICAL SENSORS
Methods and compositions for the treatment of peripheral artery disease
InactiveUS7186407B2Inhibit progressEffective treatmentOrganic active ingredientsNervous disorderSpinal claudicationVein
Compositions and methods for treating peripheral artery disease in a patient are provided. Compositions comprise recombinant fibroblast growth factor-2. Fibroblast growth factor, such as FGF-2, is administered in therapeutically effective amounts to treat or prevent peripheral artery disease including claudication and critical limb ischemia. Pharmaceutical compositions comprising a therapeutically effective amount of FGF-2 and a pharmaceutically acceptable carrier are also provided. The methods of the invention to treat peripheral artery disease and claudication comprise administering at least a single dose of a pharmaceutical composition comprising the FGF, such as FGF-2, via intra-arterial, intravenous, or intramuscular infusion to the patient. It is recognized that increased benefits may result from multiple dosing, including intermittent dosing.
Owner:NOVARTIS VACCINES & DIAGNOSTICS INC
Compounds and Methods for the Treatment of Vascular Disease
ActiveUS20100291064A1Reduce the binding forceInhibitionOrganic active ingredientsNervous disorderIschemic painMigraine
The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and / or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analogue or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and / or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and / or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.
Owner:ANNEXIN PHARMA
Kit based on 14 SNP loci for evaluating peripheral arterial disease prevalence risk
The invention discloses a kit based on 14 SNP loci for evaluating the peripheral arterial disease prevalence risk and further discloses an application for detecting a following 14 SNP locus material in preparing a product for evaluating or auxiliary evaluating of the peripheral arterial disease prevalence risk of a to-be-tested person: rs17817449 locus, rs6567160 locus, rs10938397 locus, rs6265 locus, rs574367 locus, rs4715210 locus, rs4776970 locus, rs11671664 locus, rs6545814 locus, rs9356744 locus, rs261967 locus, rs12597579 locus, rs652722 locus and rs11142387 locus. According to the kit based on 14 SNP loci for evaluating the peripheral arterial disease prevalence risk, 14 BM1 genetic loci and BMI-GRS are integrated, and the PAD prevalence risk is comprehensively evaluated; the genetic loci are tested in a large scale, and the kit is suitable for Chinese people; the test kit is economical, convenient and suitable for large-scale promotion.
Owner:CAPITALBIO CORP +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com